Abstract: When used with ritonavir, the accumulation of six or more mutations among L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/T/S and I84V leads to clear decrease in viral response to treatment.
[Study of resistance using the TRUGENE HIV-1 genotyping system and analysis of agreement between rule-based algorithms and virtual phenotyping].
PMID: 15757587
2005
Enfermedades infecciosas y microbiologia clinica
Abstract: For the IP: key mutations L90M (26.1%), M46I (18.1%) and V82AFTS (12.9%); and accessory mutations L63P (50.5%), A71V (27.2%), L10I (25.2%) and M36I (19.2%).
Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors.
PMID: 15855527
2005
Antimicrobial agents and chemotherapy
Abstr
Abstract: In particular, E34Q, K43T, and K55R, which were associated with lopinavir treatment, correlated with mutations associated with lopinavir resistance (E34Q with either L33F or F53L, or K43T with I54A) or clustered with multi-PI resistance mutations (K43T with V82A and I54V or V82A, V32I, and I47V, or K55R with V82A, I54V, and M46I).
[Genotypic resistence in patients infected with HIV and its correlation with therapy].
Abstract: A surprisingly diverse pattern of primary PI mutations was seen: M46I (n=7), D30N (n=6), L90M (n=5), and V82A (n=4).
Abstract: At baseline, the V82A mutation was found in four PI-naive patients of whom two failed therapy exhibiting this mutation.
[Genotypic antiretroviral resistance testing and phylogenetic analysis of protease and reverse transcriptase in antiretroviral drug-naive AIDS patients in Henan province].
PMID: 16053762
2005
Zhonghua liu xing bing xue za zhi
Abstract: The major mutation rate of resistance to protease was 8.3% (3/36), including types D30A, V32A, G73C and V82A.
Treatment response and drug resistance in patients infected with HIV type 1 group O viruses.
PMID: 16060830
2005
AIDS research and human retroviruses
Abstract: One selected changes M41L, E44D, D67N, V75M, M184V, and T215Y at the RT, and G48M, F53L, I54V, V82A, and L90M at the protease.
Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
PMID: 16195257
2005
The Journal of antimicrobial chemotherapy
Abstract: Children with I54V and V82A/F had higher prevalence of lopinavir-associated resistance mutations and showed RP of 0.36 (CI95%: 0.17; 0.76; P = 0.007) for achieving uVL.
Abstract: Moreover, I54V and V82A/F led to the poorest virological response.
Abstract: The relative proportion (RP) to uVL was 0.32 (CI95%: 0.16; 0.33; P = 0.002) in children with I54V (46% of total) and 0.48 (CI95%: 0.24; 0.97; P = 0.041) in children with V82A/F (52% of total).
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Abstract: PR(V82A) was able to compensate for the loss of interaction with inhibitor cause
Abstract: HIV-1 protease (PR) and two drug-resistant variants--PR with the V82A mutation (PR(V82A)) and PR with the I84V mutation (PR(I84V))--were studied using reduced peptide analogs of five natural cleavage sites (CA-p2, p2-NC, p6pol-PR, p1-p6 and NC-p1) to understand the structural and kinetic changes.
Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs.
PMID: 19825125
2005
Journal of the International AIDS Society
Table: V82A
Discussion: Other mutations resulting from G A transitions may occur rarely, such as V82T (the preferred mutation in this position is V82A, which results from a T C transition).
HIV mutation literature information.
PMID: 
2005
Drugs
Browser Board
Co-occurred Entities
Filtrator
ViMRT